Quote | RenovoRx Inc. (NASDAQ:RNXT)
Last: | $1.13 |
---|---|
Change Percent: | 3.48% |
Open: | $1.11 |
Close: | $1.13 |
High: | $1.15 |
Low: | $1.11 |
Volume: | 20,379 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | RenovoRx Inc. (NASDAQ:RNXT)
LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
Message Board Posts | RenovoRx Inc. (NASDAQ:RNXT)
Subject | By | Source | When |
---|---|---|---|
RenovoXT has avery promising and positive breaktrough technology | Stockrocketer | investorshub | 06/29/2023 4:16:53 PM |
TOILET FLUSH ROUTINE. | Invest-in-America | investorshub | 06/29/2023 3:53:58 PM |
Yea you like the chart can't hold 3 | Pt3 | investorshub | 06/29/2023 3:52:11 PM |
$RNXT: I like the 'Chart' on this one. | Invest-in-America | investorshub | 06/29/2023 1:47:02 PM |
NewsRenovoRx Announces New Positive Interim Phase III Data | tw0122 | investorshub | 06/29/2023 12:09:39 PM |
News, Short Squeeze, Breakout and More Instantly...
LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx is well positioned to advance its pivotal Phase III clinical trial, expand development pipeline into additional cancer indications and explore new commercial business development opportunities with its therapeutic t...